BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
73 results:

  • 1. Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.
    Huang R; Zhao M; Zhang G; Yang Y; Wang J; Zheng K; Li L; Su X; Zhao L; Wu Y; Zou Z
    Cancer Med; 2024 Apr; 13(7):e7137. PubMed ID: 38545846
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. tert promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
    Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
    Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
    Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
    Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Activity and Selectivity of Novel Chemical Metallic Complexes with Potential Anticancer Effects on Melanoma Cells.
    Ciardulli MC; Mariconda A; Sirignano M; Lamparelli EP; Longo R; Scala P; D'Auria R; Santoro A; Guadagno L; Della Porta G; Longo P
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375406
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring tert promoter and BRAF
    Su YJ; Cheng SH; Qian J; Zhang M; Liu W; Zhan XX; Wang ZQ; Liu HD; Zhong XW; Cheng RC
    Arch Endocrinol Metab; 2023 Jun; 67(6):e000659. PubMed ID: 37364156
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
    Kisistók J; Christensen DS; Rasmussen MH; Duval L; Aggerholm-Pedersen N; Luczak AA; Sorensen BS; Jakobsen MR; Oellegaard TH; Birkbak NJ
    Melanoma Res; 2023 Oct; 33(5):364-374. PubMed ID: 37294123
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. BRAF
    Choi JH; Yu HW; Lee JK; Kim W; Choi JY; Na HY; Park SY; Ahn CH; Moon JH; Choi SI; Lee HY; Lee WW; Cha W; Jeong WJ
    World J Surg Oncol; 2023 Feb; 21(1):49. PubMed ID: 36804879
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Compound clear cell sarcoma with EWSR1::CREM fusion.
    Li P; Busam K
    J Cutan Pathol; 2023 Dec; 50(12):1065-1069. PubMed ID: 36640048
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular and immunohistochemical comparison between primary gastrointestinal mucosal melanomas and atypical gastrointestinal stromal tumors.
    Song IH; Sung YE; Kang J; Lee A; Lee SH
    Pathol Res Pract; 2022 Dec; 240():154189. PubMed ID: 36327823
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
    Zaremba A; Jansen P; Murali R; Mayakonda A; Riedel A; Philip M; Rose C; Schaller J; Müller H; Kutzner H; Möller I; Stadtler N; Kretz J; Sucker A; Bankfalvi A; Livingstone E; Zimmer L; Horn S; Paschen A; Plass C; Schadendorf D; Hadaschik E; Lutsik P; Griewank K
    Int J Cancer; 2022 Nov; 151(9):1542-1554. PubMed ID: 35737508
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line.
    Shi C; Gu Z; Xu S; Ju H; Wu Y; Han Y; Li J; Li C; Wu J; Wang L; Li J; Zhou G; Ye W; Ren G; Zhang Z; Zhou R
    Cancer Commun (Lond); 2022 Jul; 42(7):627-647. PubMed ID: 35666052
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Phase I study of [
    Thivat E; Rouanet J; Auzeloux P; Sas N; Jouberton E; Levesque S; Billoux T; Mansard S; Molnar I; Chanchou M; Fois G; Maigne L; Chezal JM; Miot-Noirault E; D'Incan M; Durando X; Cachin F
    BMC Cancer; 2022 Apr; 22(1):417. PubMed ID: 35428211
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
    Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
    Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. tert promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
    Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
    Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Positive Attributes of Anti-tert CD4 T-Helper Type 1 Immune Responses in Melanoma.
    Nagore E; Virós A; Kumar R
    J Invest Dermatol; 2022 Feb; 142(2):279-281. PubMed ID: 34666894
    [TBL] [Abstract] [Full Text] [Related]  

  • 17.
    Zeinali S; Tuncel A; Yüzer A; Yurt F
    Photodiagnosis Photodyn Ther; 2021 Dec; 36():102518. PubMed ID: 34478898
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
    Nardin C; Laheurte C; Puzenat E; Boullerot L; Ramseyer M; Marguier A; Jacquin M; Godet Y; Aubin F; Adotevi O
    J Invest Dermatol; 2022 Feb; 142(2):435-444. PubMed ID: 34352265
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
    Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.
    Brouwer NJ; Verdijk RM; Heegaard S; Marinkovic M; Esmaeli B; Jager MJ
    Prog Retin Eye Res; 2022 Jan; 86():100971. PubMed ID: 34015548
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.